1,720,998 research outputs found
Fallimenti terapeutici nei pazienti bipolari: nuove strategie. Atti del Convegno del 21-22 gennaio 2005, Roma, realizzato in collaborazione con AstraZeneca.
No full textMemantine in the treatment and prophylaxis of bipolar II disorder and comorbid fibromyalgia. A case report
No full textWe have recently reported that memantine has a clinically relevant antimanic and long-lasting mood-stabilizing effect in treatment-resistant bipolar disorders, both as augmenting agent and as monotherapy. We have also observed an acute antimanic and sustained mood-stabilizing effect in a small number of patients with bipolar I disorder who had had minimal previous pharmacotherapy. In this article, we report the case of a young woman suffering from bipolar II disorder with associated fibromyalgia, in whom memantine showed an acute antimanic and a long-term prophylactic effect on both bipolar disorder as well as the associated fibromyalgia syndrome
Antimanic and Long-Lasting Mood Stabilizing Effect of Memantine in Bipolar I Mood Disorder Two Case Reports
No full textWe recently reported that memantine, a noncompetitiveN-methyl-D-aspartate (NMDA) receptor antagonist currently used in the treatment of Alzheimer disease, has a significant antimanic and sustained moodstabilizing effect when used as an augmenting agent in treatment-resistant bipolar mood disorders. Moreover, has been observed an acute antimanic effect of memantine monotherapy in manic patients with bipolar type I disorder (BP I). We report 2 case histories of patients with BP I successfully treated with memantine monotherapy. These 2 cases confirm that, also as a monotherapy, the drug has an acute antimanic effect
Memantine in the treatment and prophylaxis of bipolar type II mood disorder and co-morbid eating disorder. a case report [Memantina nel trattamento e nella profilassi del disturbo dell’umore bipolare di tipo II in comorbilità con disturbo del comportamento alimentare. un caso clinico]
No full textRIASSUNTO. Abbiamo recentemente riportato che la memantina ha un effetto antimaniacale clinicamente rilevante e un prolungato effetto profilattico nel disturbo bipolare resistente ai trattamenti convenzionali,sia come “augmenting” terapia sia in monoterapia.Abbiamo, inoltre, osservato un effetto antimaniacale acuto e profilattico a lungo termine in pazienti bipolari di tipo I “naïve”. Qui descriviamo la storia clinica di una giovane paziente con disturbo bipolare di tipo II associato a un grave disturbo del comportamento alimentare, che conferma che
la memantina ha un effetto antimaniacale acuto e previene le ricadute del disturbo bipolare in comorbilità con disturbi del comportamento
alimentare.We have recently reported that memantine has a clinically relevant antimanic and long-lasting mood-stabilizing effect in treatment-resistant bipolar disorders, both as augmenting agent and as a monotherapy. Moreover, we observed an acute antimanic and sustained mood-stabilizing effect also in "naive" bipolar type I disorder. Here we report a case history of a young woman suffering from bipolar type II mood disorder, associated with a very severe eating disorder, showing an acute antimanic and a long-term prophylactic effect of memantine on bipolar disorder and comorbid eating disorder
Terapia elettroconvulsivante. Razionale per lo sviluppo di future linee guida da parte dell’Associazione Italiana per la Terapia Elettroconvulsivante (AITEC). Electroconvulsive therapy. Rationale for the development of future guidelines by the Italian Association for Electroconvulsive Therapy (AITEC)
No full textSimultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients
No full textAn original method based on the use of high-performance liquid chromatography with both coulometric and diode array detection has been developed for the therapeutic drug monitoring of patients with bipolar disorders being treated with olanzapine and lamotrigine. Chromatographic separation was achieved on a reversed-phase C8 column (150 x 4.6 mm internal diameter, 5 microm) using a mobile phase composed of methanol (27%) and a 50.0 mmol/L, pH 3.5 phosphate buffer (73%). For the analysis of olanzapine and its main metabolite, N-desmethylolanzapine, a coulometric detector was used, with electrode 1 set at -200 mV and electrode 2 at +500 mV. Lamotrigine was determined using a diode array detection at 220 nm. The two detectors were connected in series. For the analysis of biological samples, a clean-up procedure was implemented by means of solid-phase extraction using phenyl cartridges and eluting the analytes with methanol; only a small volume of plasma (150 microL) was needed to analyze both olanzapine and lamotrigine. Linear responses were obtained between 0.1 and 50.0 ng mL(-1) for olanzapine, 0.1 and 25.0 ng mL(-1) for N-desmethylolanzapine, and between 0.25 and 10.0 microg mL(-1) for lamotrigine. The extraction yield values were always higher than 90% for all the analytes, with precision (expressed as relative standard deviation values) lower than 3.4%. The method was applied successfully to some human plasma samples drawn from bipolar patients undergoing combined therapy with the two drugs. Satisfactory values for accuracy were obtained, with mean recovery higher than 91%. Thus, the method appears suitable for the investigation of the chemical-clinical correlations in patients receiving therapy with olanzapine and lamotrigine
Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients
No full text
Anxious-excited depression. A mixed affective syndrome
No full textA mixed affective syndrome is described which meets the criteria for major depression but not those of the DSM III-R for a mixed state. The clinical picture is characterized by lack of motor retardation and fluent verbalization; the facial expression is animated and sometimes dramatic. Patients suffer considerably and are often tearful. They complain of inner tension and restlessness, racing thoughts and despair. Emotional lability and momentary irritability are observed. Insomnia occurs initially or with frequent early waking. Suicidal ideation occurs and makes the syndrome of concern in view of its impulsive nature. Antidepressants increase restlessness, insomnia, aggressiveness and the impulsiveness of suicidal ideation. Low-dose neuroleptics, lithium and anticonvulsivants are highly effective. A few sessions of ECT offer rapid improvement
The sustained mood-stabilizing effect of memantine in the management of treatment-resistant bipolar disorders: findings from a 12-month naturalistic trial.
No full text- …
